For instance, in a large-scale, single-center clinical trial, the STOP-HF (St Vincent’s Screening to Prevent Heart Failure) trial, 697 individuals at risk of HF underwent BNP assessment, echocardiogram, specialist follow-up, and potentiation of therapy with SRAA antagonists in cases of BNP > 50 pg/mL. This evidence concerns the gene NPPB and heart failure.